The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Second primary malignancy in patients with diffuse large B-cell lymphoma (DLBCL) receiving chimeric antigen receptor T-cell (CAR T) therapy and other systemic anti-cancer therapy: A real-world data analysis.
 
Matthew Lunning
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Lilly; EUSA Pharma; Fate Therapeutics; Genentech; Genmab; Ipsen; Kite, a Gilead company; Loxo; Novartis; Nurix; Pharmacyclics; Regeneron; Seagen; Takeda
Research Funding - Celgene (Inst); curis (Inst)
 
Omonefe Omofuma
No Relationships to Disclose
 
Mengying Li
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Christian Hampp
Employment - Regeneron; Virginia Mason Medical Center (I)
Stock and Other Ownership Interests - Regeneron
 
Matthew Phelan
Employment - KMK; Regeneron
 
Alexander Breskin
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Ping Shao
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Research Funding - Regeneron
Travel, Accommodations, Expenses - Regeneron
 
Claire Hearnden
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Saleem Shariff
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Nandita Mukherjee
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Srikanth Ambati
Employment - At the time of writing, Regeneron Pharmaceuticals, Inc.
Stock and Other Ownership Interests - At the time of writing, Regeneron Pharmaceuticals, Inc.
Patents, Royalties, Other Intellectual Property - At the time of writing, Regeneron Pharmaceuticals, Inc.
Travel, Accommodations, Expenses - At the time of writing, Regeneron Pharmaceuticals, Inc.
 
Hesham Mohamed
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Odronextamab related patents
 
Aafia Chaudhry
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Attaya Suvannasankha
Consulting or Advisory Role - GlaxoSmithKline; Janssen Oncology
Research Funding - BMS (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - Novel bone anabolic agent in the treatment of cancer bone metastasis (Inst)